Pyoderma Gangrenosum Associated with IgA Nephropathy

Yamen Homsi and Joshy Pathiparampil
State University of New York Downstate Medical Center, Brooklyn, New York, United States

Corresponding Author: Yamen Homsi, State University of New York Downstate Medical Center, Brooklyn, New York, United States, Tel: +1-718-270-1662; E-mail: yamen.homsi@downstate.edu

Received date: July 05 2018; Accepted date: October 15, 2018; Published date: October 22, 2018

Copyright: © 2018 Homsi Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Homsi Y, Pathiparampil J (2018) Pyoderma Gangrenosum Associated with IgA Nephropathy. Rheumatology (Sunnyvale) 8: 245. doi: 10.4172/2161-1149.1000245

Keywords: Pyoderma gangrenosum; IgA nephropathy

Case Report

A 54-year-old African American man presented to rheumatology clinic with chief complaint of sub-acute bilateral foot ulcerations for the past four weeks. He denied any associated symptoms. He had history of hypertension on losartan. Clinical exam revealed bilateral large ulcerations on the medial and lateral malleoli consistent with pyoderma gangrenosum (PG) (Figure 1A). Blood tests were notable for elevated C-Reactive Protein (CRP) of 19 (reference value, 0.0-8.0 mg/dl) and Erythrocyte Sedimentation Rate (ESR) of 63 (reference value, 0-20 mm/h). Rheumatology, infection, and malignancy workups were negative. Serum Protein Electrophoresis (SPEP) and Urine Protein Electrophoresis (UPEP) showed no monoclonal gammopathy. Urine analysis revealed persistent hematuria without casts. Chest x-ray was unremarkable. Patient underwent renal biopsy, which was consistent with IgA nephropathy. He was treated with prednisone 60 mg/day and Methotrexate (MTX) 12.5 mg weekly and folic acid 1 mg daily with complete resolution of PG (Figures 1B and 1C). Patient was tapered of prednisone and continued on MTX only. Hematuria disappeared with treatment.

Discussion

PG is a rare noninfectious neutrophilic dermatosis condition that can be idiopathic or associated with systemic diseases like inflammatory bowel disease, connective tissue disease, paraproteinemia, and hematological malignancy [1]. There are four different clinical variants of PG, namely, ulcerative, pustular, bullous and vegetative PG. The most common sites of PG is lower legs on the pretibial area [2]. The diagnosis of PG made by exclusion of other disorders like vasculitis, cancer and infection, and recognizing the clinical signs. Biopsy for histopathology can be used to support diagnosis. Treatment of PG can be either topical of systemic depending on severity of PG. Topical high potent corticosteroid and topic calcineurin inhibitors like tacrolimus and or pimecolimus were used with successful response. Various treatment approach like corticosteroid, Ciclosporin A, Tacrolimus, azathioprine, mycophenolate mofetil, and Thalidomide have been used in widespread and progressive cases. Tumor necrosis a inhibitors like infliximab are used in PG associated with inflammatory bowel diseases [2]. The association between PG and IgA nephropathy is extremely rare. We reviewed the English literature and we found only one case with acute renal failure attributed to IgA nephropathy in association with PG [3]. PG is a challenging medical condition to treat and an extensive workup is required to identify any potential underlying associated disease.

References